首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Tolerability and camouflaging effect of corrective make-up for acne: results of a clinical study of a novel face compact cream
【24h】

Tolerability and camouflaging effect of corrective make-up for acne: results of a clinical study of a novel face compact cream

机译:痤疮矫正化妆品的耐受性和伪装效果:一种新型紧致面霜的临床研究结果

获取原文
           

摘要

Background: A novel face compact cream (FCC) containing a new patented formulation was recently developed to provide acne patients with cosmetic camouflage for their lesions and to have beneficial effects on the multifactorial components of the disease. This pilot investigation aimed to evaluate the real-life tolerability, potential for comedogenicity and covering effect provided by this FCC. Methods: This single-center study evaluated the FCC applied once daily for 28 days in 20?females with facial acne. Tolerability was assessed by rating skin reactions on a scale from 1?=absent to 4 =evident. Comedogenicity potential was evaluated by determining the number of facial acne lesions before and after use of the FCC. The covering effect was rated in ten patients 30 minutes after application on a scale from 1 =none to 5 =excellent. Patients rated their opinions on the FCC on day 28 using a questionnaire. Results: Assessment of tolerability on days 0, 14, and 28 showed that skin reactions, including erythema, edema, dryness, desquamation, tight feeling, itching, and burning, were absent in all patients. The FCC was noncomedogenic and provided a significant 15.8% reduction in facial acne lesions after 28 days ( P <0.001). The FCC provided a good covering effect 30 minutes after application in 80% of patients. All patients (100%) were satisfied with the FCC, with 90% agreeing that the FCC was effective and 80% stating that the FCC improved their skin. Conclusion: The FCC was positively perceived, well tolerated, noncomedogenic, and provided an effective covering of acne in this small group of female patients with 1 month of follow-up.
机译:背景:最近开发了一种含有新专利配方的新型紧致面霜(FCC),可为痤疮患者的病变提供化妆品伪装,并对疾病的多种因素产生有益作用。该初步调查旨在评估该FCC提供的现实生活中的耐受性,潜在的粉刺性和覆盖效果。方法:这项单中心研究评估了FCC在20例面部痤疮女性中每天应用28天。耐受性是通过对皮肤反应的等级从1 =缺失到4 =明显来评估的。通过确定使用FCC之前和之后面部痤疮病变的数量来评估潜在的致粉刺性。施用后30分钟,对10位患者的覆盖效果进行了评分,从1 =无到5 =优秀。患者在第28天使用问卷对他们的意见进行了评估。结果:在第0、14和28天的耐受性评估显示,所有患者均未出现皮肤反应,包括红斑,浮肿,干燥,脱屑,紧绷感,瘙痒和灼热。 FCC是非粉刺的,可在28天后使面部痤疮病变明显减少15.8%(P <0.001)。在80%的患者应用后30分钟,FCC的覆盖效果良好。所有患者(100%)均对FCC感到满意,其中90%的人认为FCC有效,80%的人表示FCC改善了皮肤。结论:FCC被积极感知,耐受性良好,无粉刺性,可有效覆盖这一小部分女性患者的痤疮,并进行1个月的随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号